Adrian C. Begg

TL;DR: Improved understanding of the molecular response of cells and tissues to ionizing radiation and a new appreciation of the exploitable genetic alterations in tumours have led to the development of treatments combining pharmacological interventions with ionizing Radiation that more specifically target either tumour or normal tissue, leading to improvements in efficacy.

TL;DR: This trial shows that accelerated radiotherapy improves loco-regional control in head and neck squamous cell carcinomas and a less toxic scheme should be investigated and documented before using accelerate radiotherapy as a standard regimen of curative radiotherapy for head and head cancers.

TL;DR: An overview of the factors that are correlated with outcome—including survival, recurrence patterns and toxicity—in radiation oncology is provided and the methodology behind the development of prediction models is discussed, which is a multistage process.

TL;DR: A robust multigene expression model of intrinsic tumor radiosensitivity in three independent cohorts totaling 118 patients is validated, the first time that a systems biology-based radiosensitivity model is validated in multiple independent clinical datasets.

TL;DR: The combined pharmacokinetic and adduct data in patients support the advantages of the intraperitoneal route for drug administration, and the addition of heat.